Antibodies and related molecules that bind to PSCA proteins
An antibody, molecular technology, used in the prediction, prevention and treatment methods and compositions, in the field of cancer diagnosis, which can solve problems such as limitations
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0125]Preparation and screening of combinatorial libraries is well known to those skilled in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka, Pept. )), peptoids (PCT Publication WO 91 / 19735), encoded peptides (PCT Publication WO 93 / 20242), random biooligomers (PCT Publication WO 92 / 00091), benzodiazepines (US Patent No. 5,288,514 ), diversomers such as hydantoin, benzodiazepines and dipeptides (Hobbs et al., Proc.Nat.Acad.Sci.USA90: 6909-6913 (1993)), intercalated polypeptides (Hagihara et al., J.Amer .Chem.Soc.114:6568 (1992)), a non-peptide peptidomimetic (Hirschmann et al., J.Amer.Chem.Soc.114:9217-9218 (1992)) with β-D-glucose scaffold, small Similar organic synthesis libraries of compounds (Chen et al., J.Amer.Chem.Soc. 116:2661 (1994)), oligocarbarnate (Cho et al., Science 261:1303 (1993)), and / or peptide phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See gener...
Embodiment 1
[0567] Expression analysis of PSCA variants in normal tissues and patient samples
[0568] PSCA is referred to herein as PSCA v.1, and previous studies have demonstrated that PSCA is expressed as an antigen in prostate cancer. PSCA is expressed in more than 80% of primary prostate cancers and in most prostate metastases. PSCA is also expressed in gallbladder, ovary, and pancreatic cancers; tumors of this type are listed in Table I. By immunohistochemical analysis, it was found that PSCA was overexpressed on the cell surface of most transitional cell carcinomas of the urethra and 60% of primary pancreatic adenocarcinomas. In many patent documents (PCT / US98 / 04664, PCT / US / 28883, PCT / US00 / 19967) and peer-reviewed articles (Saffran et al., Proc NatlAcad Sci USA.2001-2-27;98(5):2658- 2663; Amara et al., Cancer Res. 2001-6-15; 61(12): 4660-65; Reiter et al., Proc Natl Acad Sci USA. 1998-2-17; 95(4): 1735-40; Argani et al., Cancer Res. 2001-6-1; 61(11): 4320-24) all reported data...
Embodiment 2
[0577] splice variant of PSCA
[0578] The term "variant" as used herein includes transcript variants and single nucleotide polymorphisms (SNPs). Transcript variants are variants of the mature mRNA of the same gene that result from alternative transcription or alternative splicing. Alternative transcripts are transcripts from the same gene but with different transcription initiation sites. Splice variants refer to mRNA variants formed by different splicing of the same transcript. In eukaryotes, when a multi-exon gene is transcribed from genomic DNA, the resulting RNA precursor needs to be spliced to form a functional mRNA, which has only one exon for translation into amino acids sequence. Correspondingly, a given gene may have zero to many different alternative transcripts, and each transcript may have zero to many splice variants. Each transcript variant is composed of its unique exons, containing different coding and / or non-coding (5' or 3' end) parts of the precurso...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More